-
St. Jude names Ellis Neufeld, M.D., Ph.D., clinical director and physician-in-chief
12/14/2016
Esteemed hematologist will lead clinical efforts and related expansions to patient care programs
-
Mystery molecule is a key to inhibiting colon cancer
12/12/2016
Mystery sensor protein NLRC3 revealed as a central player in preventing colon cells from becoming cancerous
-
Loss of ARID1A protein drives onset and progress of colon cancer
12/12/2016
Research reveals principal tumor suppressor function of ARID1A and suggests that loss of the protein contributes to colon cancer
-
The latest advances in the study of blood diseases presented at annual meeting of ASH
12/02/2016
St. Jude scientists and clinicians present research and thought leadership at the annual meeting of the American Society of Hematology in San Diego.
-
Small RNA identified that offers clues for quieting the “voices” of schizophrenia
11/28/2016
Researchers identify a microRNA that may be key to restoring normal functioning of a brain circuit and quieting the “voices” of schizophrenia
-
Prevalence of Ph-like ALL in adults underscores need for genetic testing, clinical trials
11/21/2016
Ph-like ALL accounts for significant percentage of acute lymphoblastic leukemia in adults, underscoring need for clinical trials of targeted
-
Potential targeted therapy found for newly identified leukemia subtype with poor outcome
11/08/2016
The MEF2D-rearranged subtype of acute lymphoblastic leukemia (ALL) is linked to poor outcomes. Now a possible targeted therapy has been identified.
-
Childhood cancer survivors are living longer but do not report improvement in health status
11/07/2016
Childhood Cancer Survivor Study reveals patients do not report better health status despite gains in life expectancy due to advances in cancer treatment
-
Patient safety benefits when hospitals provide feedback to staff who report errors
11/01/2016
To improve patient safety, hospital leaders should provide feedback that demonstrates to staff the value of reporting safety events and errors.
-
Researchers reveal genomic landscape of core-binding factor acute myeloid leukemia
10/31/2016
Research from the Pediatric Cancer Genome Project identifies genomic landscape that contributes to the diversity of core-binding factor acute myeloid leukemia.
-
Genetic hallmarks of acute lymphoblastic leukemia subtype uncovered
10/24/2016
Research from the Pediatric Cancer Genome Project identifies the mechanism of action for two transcription factors underlying a type of B-precursor acute lymphoblastic leukemia.
-
Toxic peptides disrupt membrane-less organelles in neurodegenerative disease
10/20/2016
New findings help increase understanding of molecular mechanisms for common forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
-
Janice English named director of Patient and Family Experience Office at St. Jude Children’s Research Hospital
10/13/2016
Under her direction, the office leads a concentrated effort to enhance the patient and family experience at St. Jude.
-
Triple-drug chemotherapy with topotecan helps preserve vision in retinoblastoma patients
10/10/2016
Chemotherapy drug topotecan aids cure and vision preservation in patients with advanced retinoblastoma, while reducing risk of treatment late effects.
-
Scientists reveal how signals from pathogenic bacteria reach danger sensors of cells
09/29/2016
Researchers identify the molecular events that activate inflammasomes to initiate the innate immune response against bacterial invaders.
-
Newly discovered immune cell type protects against lung infections during chemotherapy
09/26/2016
Newly recognized lung macrophage protects chemotherapy-treated mice with a depleted immune system from lethal bacterial pneumonia
-
New mobile health app will help sickle cell patients stay healthy
09/21/2016
National Institutes of Health funding will help physicians and researchers improve hydroxyurea treatment management for sickle cell patients in Memphis.
-
St. Jude and Methodist Healthcare sign agreement to advance center for adult sickle cell disease in Memphis
09/19/2016
The newly expanded Methodist Comprehensive Sickle Cell Center will strengthen research into sickle cell disease and serve the growing needs of patients in the Memphis area.
-
St. Jude Children’s Research Hospital and Sanger Institute, UK collaborate to make data beautiful
09/16/2016
Proteinpaint database collaboration will make it easier for any scientist to explore cancer genome data.
-
Applications now being accepted for inaugural class of St. Jude Graduate School of Biomedical Sciences
09/01/2016
The new doctoral program will focus on translational research and integrated approaches to discover better treatments and cures for pediatric diseases.
-
Stem cell propagation fuels cancer risk in different organs
08/25/2016
St. Jude researchers provide experimental evidence to demonstrate how stem cells contribute to cancer risk.
-
St. Jude Children’s Research Hospital appoints scientific director
08/24/2016
James Morgan, Ph.D., will lead the institution’s basic science programs
-
CRISPR gene editing reveals new therapeutic approach for blood disorders
08/15/2016
Researchers found a way to use genome editing to help fix sickle cell disease and beta-thalassemia in blood cells isolated from patients.
-
St. Jude researchers pinpoint key influenza-fighting immune trigger
08/12/2016
Molecular "master assassin" identified that recognizes flu-infected cells and triggers cell death, raises hope for drugs to prevent flu complications.
-
Rare genetic variations may solve mystery of porphyria severity in some patients
08/10/2016
Variations in a porphyrin transport protein may affect symptom severity in patients with porphyria, a rare disorder of skin, liver and nervous system.
-
Vaccines fail to protect obese mice from severe influenza infections
08/02/2016
The addition of adjuvants to influenza vaccines offers no protection from severe flu infections in study looking at obesity.
-
Novel statistical method captures long-term health burden of pediatric cancer cures
07/25/2016
Researchers develop “cumulative burden” statistical method to measure and address the impact of chronic disease in childhood cancer survivors
-
Evidence suggests migratory birds are not a reservoir for highly pathogenic flu viruses
07/25/2016
Influenza surveillance in migratory waterfowl suggests that highly pathogenic avian flu viruses do not persist in wild aquatic birds
-
Pharmacogenetics experts establish common vocabulary in bid to advance precision medicine
07/21/2016
Experts have developed a list of preferred terms to promote standardize reporting of pharmacogenetic test results in patients’ health records
-
Some adolescent cancer survivors may require more comprehensive mental health screening
07/18/2016
Study shows that most teen cancer survivors do well psychologically, but cancer treatment may influence some survivors’ symptoms
-
Loss of essential protein in the choroid plexus epithelium linked to hydrocephalus
06/23/2016
Multifunctional protein Alix identified as essential for maintaining fluid balance in the brain; loss is linked to hydrocephalus.
-
St. Jude becomes first children’s hospital in U.S. to earn CAP ISO15189 accreditation
06/16/2016
The Department of Pathology has been accredited by The College of American Pathologists (CAP), a Centers for Medicare and Medicaid Services (CMS)-approved accreditation authority.
-
St. Jude Children’s Research Hospital scientist named Pew-Stewart Scholar
06/09/2016
St. Jude scientist studying medulloblastoma is named Pew-Stewart Scholar for Cancer Research, which supports innovative early career researchers
-
St. Jude Children's Research Hospital names Department of Developmental Neurobiology chair
06/08/2016
Michael Dyer, Ph.D., to chair the department and build a team of international leaders in neural development, synapse formation and neural circuit formation.
-
Methotrexate exposure impacts cognitive processes cancer survivors need to multitask
06/06/2016
Higher blood levels of methotrexate during treatment of childhood leukemia have been linked to diminished executive function in long-term survivors.
-
St. Jude Children’s Research Hospital research being presented at ASCO Annual Meeting
06/03/2016
St. Jude experts present their research at the annual meeting of the American Society of Clinical Oncology in Chicago.
-
Investigational immunotherapy drug shrinks tumors in high-risk neuroblastoma patients
06/03/2016
Preliminary report: Neuroblastoma tumors shrank in more pediatric patients when experimental immunotherapy was combined with chemotherapy
-
James R. Downing, M.D., tells podcast audience about St. Jude mission and global goals
05/23/2016
St. Jude president and chief executive officer discusses giving all children the best chance against cancer and other illnesses on the Innovate podcast series.
-
Enzyme pair play crucial role in maintaining balance of cellular processes
05/19/2016
Enzymes best known for their role in autophagy also play a pivotal role in protein trafficking that helps maintain brain cell health.
-
Children with brain tumors undergoing radiation therapy helped by play-based preparation
05/18/2016
Child life specialists show support interventions decrease sedation use for radiation therapy.
-
Modeling and simulation help optimize chemotherapy to combat brain tumor
05/10/2016
Pharmacologic modeling and simulation help translate preclinical data into phase I trial of the drug 5-FU for treatment of brain tumor ependymoma.
-
Targeted antibiotic is easier on the gut microbiome
05/09/2016
Pathogen-specific antibiotic is less likely to kill good bacteria in gut, raising hopes for reduced side effects caused by disruption of microbiome.
-
Risk factors identified for acute pancreatitis that can disrupt leukemia treatment
04/25/2016
Native American ancestry and rare CPA2 gene variation may leave some leukemia patients at risk of pancreatitis following treatment with asparaginase.
-
Gene therapy pioneered at St. Jude shows early success against "bubble boy" disease
04/20/2016
Health and immune function improved in patients with X-linked SCID, or bubble boy disease, who underwent gene therapy after other treatments failed.
-
Defects in the body’s cell disposal system may contribute to the most common form of lupus
04/20/2016
A casual observation leads to discovery that defects in a cell disposal system called LAP may lead to a lupus-like autoimmune disorder
-
James R. Downing, M.D., of St. Jude, elected to the American Academy of Arts and Sciences
04/20/2016
St. Jude Children’s Research Hospital president and CEO joins the 236th class of members, which includes national and international scholars, artists, philanthropists and leaders.
-
St. Jude researchers reveal how two types of immune cells can arise from one
04/11/2016
Lopsided distribution of the signaling protein c-Myc plays a critical role in determining T cell destiny during asymmetric cell division.
-
James R. Downing, M.D., of St. Jude, to advise National Cancer Moonshot Initiative
04/04/2016
The Blue Ribbon Panel will serve as a working group for presidentially-appointed National Cancer Advisory Board.
-
St. Jude research will guide development of new anti-influenza drugs
03/14/2016
Researchers lay the foundation for a new class of influenza drugs that will be tougher for flu viruses to resist.
-
Maternal bacterial infections trigger abnormal proliferation of neurons in fetal brain
03/09/2016
Neuronal proliferation, not cell death, may help explain why bacterial infections during pregnancy lead to cognitive problems in children.
-
St. Jude Children's Research Hospital named to Fortune magazine’s "100 Best Companies to Work For" for sixth consecutive year
03/03/2016
St. Jude was included again on Fortune's annual list for having exceptional workplace culture based upon employee surveys and an in-depth questionnaire.
-
Scientists reveal alternative route for cell death
03/03/2016
The protein BOK is involved in the mitochondrial cell death pathway, discovered by St. Jude researchers. This pathway ensures the rapid, programmed destruction of the cell and its contents.
-
Protein revealed as glue that holds biomolecules within the nucleolus
03/01/2016
Research reveals how the protein NPM1 lays foundation for ribosome assembly in the nucleolus through a process called liquid-liquid phase separation.
-
Capsule Shedding: A new bacterial pathway that promotes invasive disease
02/29/2016
Suicide enzyme LytA helps pneumococcus bacteria rapidly shed capsule to evade early immune response and set the stage for invasive disease
-
Discovery of likely subtypes of rare childhood brain tumor signals diagnostic advance
02/25/2016
Molecular classification of rare brain tumors CNS-PNET likely to improve diagnosis and set stage for targeted therapies.
-
Newly identified genes impact how transplanted stem cells give rise to blood cells
02/15/2016
Researchers investigate methods to enhance the utilization of blood-forming stem cells by identifying genes needed for successful transplantation.
-
Discovery lays the foundation to expand personalized chemotherapy for leukemia patients
02/15/2016
Researchers show how inherited variations in NUDT15 gene, which are most common in Asian and Hispanic patients, cause thiopurine drug toxicity.
-
St. Jude Children’s Research Hospital welcomes Pat Keel as chief financial officer
02/11/2016
Keel will lead the financial strategy and management for St. Jude to reach the hospital’s goals of growth and innovation.
-
Attention problems persist in childhood leukemia survivors treated with chemotherapy alone
02/10/2016
Despite an end to cranial irradiation for treatment of pediatric acute lymphoblastic leukemia (ALL), survivors remain at risk for attention problems.
-
Scientists discover a unique mechanism for a high-risk leukemia
02/08/2016
St. Jude researchers discover how chromosomal rearrangements trigger a high-risk acute lymphoblastic leukemia, and identify strong treatment leads.
-
Study finds significant cognitive impairment in adult survivors of childhood brain tumors
02/01/2016
St. Jude LIFE study reports that decades after treatment, adult survivors of childhood brain tumors often face significant cognitive challenges.
-
Drug counters effects of excessive inflammation arising from immune disorder
01/29/2016
Researchers demonstrate drugs’ effectiveness in targeting immune reactions and show potential clinical trial application.
-
Researchers mine the epigenome to identify likely origins of childhood brain tumor subtype
01/27/2016
Epigenome yields insights into medulloblastoma, the most common malignant pediatric brain tumor, including likely cell of origin for Group 4 subtype.
-
Acid-sensitive molecular changes contribute to the emergence of pandemic influenza
01/25/2016
Tracking the 2009 H1N1 pandemic flu virus revealed that hemagglutinin acid stability is required for person-to-person spread of pandemic viruses.
-
Sequencing reveals genetic alterations for uncommon brain tumors in children
01/25/2016
Pediatric Cancer Genome Project identifies high-frequency driver mutations in low-grade neuroepithelial tumors that may lead to new treatment options.
-
Discovery reveals how protective immune cells protect themselves
01/25/2016
Mechanism identified that protects regulatory T cells working to maintain balanced immune response; may offer possible immune therapies for cancer.
-
New drug target identified for X-linked lymphoproliferative disease
01/13/2016
Study shows that inhibition of enzyme could reverse life-threatening effects of immunodeficiency disease.
-
Long-term survivors of childhood cancer living longer thanks in part to treatment changes
01/13/2016
Study shows the 15-year death rate among childhood cancer survivors has decreased steadily since 1970, coinciding with changes in pediatric cancer therapy and follow-up care.
-
Scientists identify protein interaction that defines an aggressive brain tumor subtype
01/11/2016
Researchers identify Myc-Miz1 protein interaction as a hallmark of aggressive group 3 medulloblastoma tumors and also a potential treatment.
-
St. Jude Children’s Research Hospital names police department veteran Toney Armstrong director of security
01/07/2016
Armstrong joins St. Jude to oversee all security operations on the hospital’s growing campus and in its patient housing facilities.
